DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0%
Mon, 4 Feb

DR. REDDYS LAB has announced its results for the quarter ended December 2018. Here is a detailed performance review of the same:

DR. REDDYS LAB Quarterly Financials

No. of Mths
Qtr. Ending
3
Dec-17*
3
Sep-18*
3
Dec-18*
QoQ ChangeYoY Change
Net SalesRs m38,34138,17538,6461.2%0.8%
Other incomeRs m4301,2821,023-20.2%137.9%
TurnoverRs m38,77139,45739,6690.5%2.3%
ExpensesRs m30,41430,58230,6000.1%0.6%
Gross profitRs m7,9277,5938,0466.0%1.5%
DepreciationRs m2,7152,7862,9034.2%6.9%
InterestRs m17220824115.9%40.1%
Profit before taxRs m5,4705,8815,9250.7%8.3%
TaxRs m2,5288071,01125.3%-60.0%
Profit after taxRs m2,9425,0744,914-3.2%67.0%
Gross profit margin%20.719.920.8
Effective tax rate%46.213.717.1
Net profit margin%7.612.912.4
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 0.8% on a year-on-year (YoY) basis. The expenses were up by 0.6% YoY during the same period.
  • The company's operating profit increased by 1.5% YoY during the quarter. Consequently, operating profit margins remained same and stood at 20.8% in 3QFY19.
  • Depreciation charges increased by 6.9% and finance costs increased by 40.1% YoY, respectively.
  • Other income increased by 137.9% YoY during the quarter.
  • Net profit for the quarter increased by 67.0% YoY. Net profit margins during the quarter increased from 7.6% in 3QFY18 to 12.4% in 3QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 1.2% on a quarter-on-quarter (QoQ) basis. The expenses were up by 0.1% QoQ during the same period.
  • The company's operating profit increased by 6.0% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 20.8% in 3QFY19 as against 19.9% in 2QFY18.
  • Net profit for the quarter declined by 3.2% QoQ, while net profit margins declined from 12.9% in 2QFY18 to 12.4% in 3QFY19.

To see how DR. REDDYS LAB has performed over the last eight quarters, please visit here.

DR. REDDYS LAB Share Price Performance

Over the last one year, DR. REDDYS LAB share price has moved up from Rs 2,122.1 to Rs 2,756.0, registering a Gain of Rs 633.9 or around 29.9%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,823.0 (down 1.2%). Over the last one year it has moved down from 14,067.6 to 13,823.0, a gain of 245 points (down 1.7%).

Overall, the S&P BSE SENSEX is up 1.5% over the year.

Current Valuations

At the current price of Rs 2,756.0, the price to earnings (P/E) ratio of DR. REDDYS LAB stands at 26.1 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.6 times.

Equitymaster requests your view! Post a comment on "DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0%". Click here!

  

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus(Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Real Long-Term Impact of the Coronavirus on India(The 5 Minute Wrapup)

Mar 18, 2020

My view on the impact of the Coronavirus on the Indian economy.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Mar 27, 2020 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - TEVA PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS